patrick

[Stephen Flynn @StephenFlynnSNP]

The greatest commentary in the history of commentary

[Scotland National Team @ScotlandNT]

McTominay. Shanks. KT. The Mayor.

Proof that last night did happen ⤵️

#FIFAWorldCup | @FIFAWorldCup

[Pharmacy - Austin Health, Australia @Austin_HealthRx]

New article from @Austin_Health senior #IBD pharmacist Patrick Hilley: Implementation of values-based healthcare in inflammatory bowel disease—a review. https://t.co/hrSX4V9lkK

[Ashish Srinivasan MD PhD @Gastro_Ash]

📌Biologic safety in #IBD post liver transplant - what’s safest?

💊Gut-specific (VDZ) v systemic (aTNF, UST) agents = similar infectious events

⚠️ Steroid co-therapy = ⬆️ severe infections

Out in AP&T
🔗https://t.co/RnL9HSrGf2
👏Congrats #SimoneChin!

#GITwitter #livertwitter

[patrick @philley89]

@ruaridh_jackson Dame tavern, dame lane!

[Pharmacy - Austin Health, Australia @Austin_HealthRx]

Pharmacist integration into inflammatory bowel disease multidisciplinary teams - what are their roles, & what value do they add? A literature review from our IBD pharmacist @philley89 and MD co-authors. https://t.co/OTJfbMpzd1

[Beatriz Gros @Bealoquebea]

PREDICT UC trial optimizing infliximab dose in patients with #ASUC

Initially no differences at day 8 BUT
✅intensified better if albumin<25
✅ intensified better if crp>50

Presented by Matthew Chuen Seng Choy at @DDWMeeting #DDW2024

[Pharmacy - Austin Health, Australia @Austin_HealthRx]

Just published, co-authored by IBD pharmacist Patrick Hilley: Safety & effectiveness of Janus kinase (JAK) inhibitors in the management of inflammatory bowel disease following liver transplantation. https://t.co/Kt8Q6VHshw

[patrick @philley89]

@IBDGastroDocSg @IBDPharmacist @DrMattChoy @Gastro_Ash

[Melbourne Academic Centre for Health @MACHAustralia]

The 2024 MacHSR Future Leaders Fellowship is open to established clinicians looking to do health services research. You'll gain:
• Formal HSR training
• Protected research time
• Expert supervision
• Networking opportunities

Learn more & apply today: https://t.co/9bpDUV2fJs

[patrick @philley89]

@AndyGoode10 @Nigel_Farage @GBNEWS @jimhamilton4 time to cut loose I reckon.

[patrick @philley89]

@AndyGoode10 @Nigel_Farage @GBNEWS Dislike, get a grip @AndyGoode10

[the limbic @thelimbicgastro]

Switching patients with IBD from intravenous to subcutaneous biologics might improve convenience for patients but results in a financial loss to health services, an Australian study suggests. https://t.co/KsXFnmTNlF

[patrick @philley89]

Opportunity cost of improving access to healthcare via switch to subcutaneous infliximab and vedolizumab.
https://t.co/3WKc5D8pjX

[patrick @philley89]

@86TVsband melbourne next?

[patrick @philley89]

@AndyGoode10 @jamesdrewturner

[Ashish Srinivasan MD PhD @Gastro_Ash]

Outcomes out to 12 months after sequential use of high‐dose tofacitinib following infliximab in acute severe ulcerative colitis - Eqbal - 2023 - Internal Medicine Journal - Wiley Online Library https://t.co/JntOWGsPCL

@philley89 @DrMattChoy

[patrick @philley89]

@ShomronH @IBDcanruti @hgermanstrias @CIBERehd @GTRecerca @DrMattChoy

[patrick @philley89]

@RoryStewartUK Prince Andrew give you any recommendations?

[Ellie Johnson @ellierjohnson]

We want to improve patient experience of abortion care in Melbourne’s north.
https://t.co/7U9HCFzS6P
@kate_chaouki @LisaHui4 @cmvaug @BodilRasmussen4